Thanks Dr T, hopefully the secondary anti cancer endpoints get enough time to give us the ‘zag’ part of the equation. Although the risk of not getting enough supporting data for that does appear to be offset by earlier evidence of efficacy in multiple cancers/indications. Smaller bite but still more piece of the pie?
One other item that came up from the AGM was the mention of China as a potential early market for bisantrene. Without knowing what shape an early pre approval deal could look like in that part of the world it does seem to be worth a shot. Interested to see if you and Pete can make anything happen there.
Thanks Dr T, hopefully the secondary anti cancer endpoints get...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.22 |
Change
-0.010(0.81%) |
Mkt cap ! $202.7M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.26 | $1.14 | $381.6K | 320.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7000 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 2171 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.17 |
Change
-0.010 ( 5.54 %) |
||||
| Open | High | Low | Volume | ||
| $1.23 | $1.23 | $1.14 | 48407 | ||
| Last updated 15.52pm 03/05/2024 ? | |||||
| RAC (ASX) Chart |